SCHEMBL3717205

SCHEMBL3717205

O=C(O)c1cn[c]c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 5/20 0.48
TPMT P51580 1/20 0.41
TSHR P16473 3/20 0.40
ALOX15 P16050 3/20 0.40
HIF1A Q16665 1/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.39
DDO Q99489 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
TTR P02766 1/20 0.39
HCAR1 Q9BXC0 1/20 0.36
DAO P14920 1/20 0.36
KDM6B O15054 1/20 0.35
TET3 O43151 1/20 0.35
KDM4A O75164 1/20 0.35
BBOX1 O75936 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4926896 0.82 CA5A (0.35) HCAR2MEN1KMT2ALMNAMAPT
SCHEMBL1032198 0.77 ATM (0.47) TSHRKDM4EALDH1A1MEN1KMT2A
SCHEMBL8721421 0.77 ALOX15 (0.41) HCAR2TSHRALOX15HIF1AKDM4E
SCHEMBL11729556 0.75 HCAR2 (0.48) HCAR2TSHRALOX15HIF1AKDM4E
SCHEMBL3713189 0.75 HCAR2 (0.48) HCAR2TSHRALOX15HIF1AKDM4E
SCHEMBL3706563 0.75 HCAR2 (0.48) HCAR2TPMTTSHRALOX15HIF1A
SCHEMBL11731520 0.75 ALOX15 (0.45) HCAR2TPMTTSHRALOX15HIF1A
SCHEMBL3719013 0.73 HPGD (0.49) TSHRKDM4EALDH1A1MEN1KMT2A
SCHEMBL6948936 0.70 TPMT (0.56) HCAR2TPMTTSHRALOX15HIF1A
SCHEMBL2440695 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 EP claimed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 US claimed
EP-2479165-A1 GLYCINE COMPOUND Astellas Pharma Inc. (JP) 2012-07-25 EP claimed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 US claimed
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 US disclosed
EP-2479165-A1 GLYCINE COMPOUND Astellas Pharma Inc. (JP) 2012-07-25 EP disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 US disclosed
WO-2010092342-A1 ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 WO disclosed
US-4009168-A STABILIZERS FOR POLYOLEFINS UBE INDUSTRIES, LTD. (JA) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB HCAR2 3140/4885TPMT 2462/4885TSHR 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.